Save on Blinatumomab with Coupons, Discounts & Savings Programs

Blinatumomab is available as 35 mcg in a single-dose vial.

Blinatumomab is a monoclonal antibody that is used to treat:

• CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL)

Blinatumomab works by helping your immune system slow or stop the spread of cancer cells. It is a monoclonal antibody.

Blinatumomab dose is based on weight and schedule. You will be hospitalized for part of the first cycle.

Blinatumomab is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Blinatumomab:

• Fever
• Infusion-related reactions
• Infections
• Headache
• Neutropenia
• Anemia
• Thrombocytopenia

Serious side effects are rare with Blinatumomab. Call your healthcare provider or get emergency medical help right away if you get any of the symptoms listed
below.

• Cytokine Release Syndrome (CRS) and Infusion Reactions: fever, tiredness or weakness, dizziness, headache, low blood pressure, nausea, vomiting, face swelling, wheezing or trouble breathing and skin rash
• Neurologic problems: seizures, difficulty in speaking or slurred speech, loss of consciousness, trouble sleeping, confusion and disorientation, loss of balance, difficulty with facial movements, hearing, vision, or swallowing, and tremors

No formal drug interaction studies have been conducted with Blinatumomab. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

Blinatumomab may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with Blinatumomab. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Blinatumomab. Females who are able to become pregnant should use an effective form of birth control during treatment with Blinatumomab, and for 48 hours after your last dose of Blinatumomab.

• Blincyto